Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2003

View Archived Issues

Four series of antiangiogenic peptides described by Abbott scientists

Merck claims novel tyrosine kinase inhibitors for use in cancer and other disorders

New PTP inhibitors prepared and tested at Applied Research Systems

Neurotrophic and neuroprotective agents identified by Toyama researchers

New HCV NS5B polymerase inhibitors in GSK development pipeline

Inhibitors of IKK2 and potential uses described in recent patent

New adenosine antagonists with utility in constipation, IBS, etc., covered by Eisai patent

Selenium reduces the risk of progression toward cancer in patients with Barrett's esophagus

Initial phase III results for canker sore treatment OraDisc A

Generex schedules Canadian phase IIb trials of Oralin

Cellegy appoints Neopharm to distribute Tostrex in Israel

Femara increases survival in advanced breast cancer

Fuzeon approved in E.U.

NM-702 enters late phase II trial for chronic arterial occlusion

DB-289 enters phase IIb PCP trial

Results for Thalomid and IMiDs in all stages of multiple myeloma

Arimidex evaluated in women at high risk for breast cancer, very early breast cancer

IND filed for Corus-1020, first patient enrolled in cystic fibrosis study

Orphan drug status awarded to KSB-303 for pancreatic cancer

Medarex reports preclinical results for anthrax antibody

Lilly terminates licensing agreement with Ono

PT-100 shows promise in chemotherapy-induced neutropenia

IND cleared for VaxGen's anthrax vaccine

Protherics intends to acquire Enact

Preliminary evaluation of novel 5-HT2B antagonist indicates potential in IBS

Prous Science announces the publication of a comprehensive review on SARS

Selective eradication of H. pylori with BYK-170424

Inotek advances orally active PARP inhibitor through clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...